glp-1 and gip/glp-1 medications GLP-1-based therapies: current knowledge of differences between native Can Type 1 and Type

In: Proceedings of international conference on life Science and Technology

The dual-agonist mechanism may provide additional metabolic benefits, though individual responses vary

The most common adverse effects from the SURMOUNT trials include: Nausea: 24-33% of participants (dose-dependent) Diarrhea: 18-25% of participants Constipation: 13-17% of participants Vomiting: 8-12% of participants Decreased appetite: 10-15% of participants Most of these effects are mild to moderate and occur primarily during dose escalation periods

If left untreated, this can cause health problems, such as vision loss, heart disease, and kidney failure

Mounjaro (tirzepatide): EPAR product information

Hexarelin mimics this effect but offers greater chemical stability and functional potency compared to ghrelin